HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Neutral 64.5%

Neg 0% Neu 64.5% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $110 to $100.